Immunosuppression in kidney transplantation;Immunosuppression en transplantation rénale

Annales d'Urologie

Volumn 41, Issue 6, 2007, Pages 276-284

  Legendre, C ^a   Zuber, J ^a   Anglicheau, D ^a   Le Quintrec, M ^a   Martinez, F ^a   Mamzer Bruneel, M F ^a   Thervet, E ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Anti calcineurins; Immunosuppression; Kidney transplantation; mTOR inhibitors; Mycophenolate mofetil

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CD28 ANTIGEN; CD40 LIGAND; CYCLOPHILIN; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; GLUCOCORTICOID; HLA ANTIGEN; INTERLEUKIN 2; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PROTEIN KINASE ZAP 70; RAPAMYCIN; RITUXIMAB; STEROID; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR NFAT; UNINDEXED DRUG; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

APOPTOSIS; DIALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG USE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESPAN; QUALITY OF LIFE; SHORT SURVEY; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DISEASE PREDISPOSITION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; INFECTION; KIDNEY DISEASE; METHODOLOGY; NEOPLASM; REVIEW; T LYMPHOCYTE SUBPOPULATION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; DISEASE SUSCEPTIBILITY; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MODELS, IMMUNOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 36148982642     PISSN: 00034401     EISSN: 17683378     Source Type: Journal    
DOI: 10.1016/j.anuro.2007.08.006     Document Type: Short Survey

References (47)

1. Wolfe R.A., Ashby V.B., Milford E.L., Ojo A.O., Ettenger R.E., Agodoa L.Y., et al. Comparison of mortality in all patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 342 (1999) 1725-1730
2. Hariharan S., McBride M.A., and Cohen E.P. Evolution of endpoints for renal transplant outcome. Am. J. Transplant. 8 (2003) 933-941
3. Alonso A., and Oliver J. Causes of death and mortality risk factors. Nephrol. Dial. Transplant. 19 suppl3 (2004) 8-10
4. Pascual M., Theruvath T., Kawai T., Tolkoff-Rubin N., and Cosimi A.B. Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med. 346 (2002) 580-590
5. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 353 (2005) 770-781
6. Khoury S.J., and Sayegh M.H. The roles of the new negative T cell co-stimulatory pathways in regulating autoimmunity. Immunity 20 (2004) 529-538
7. Changelian P.S., Flanagan M.E., Ball D.J., Kent C.R., Magnuson K.S., Martin W.H., et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 32 (2003) 875-878
8. ® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 36 (2006) 484-489
9. Brinkmann V., Cyster J.G., and Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4 (2004) 1019-1025
10. Clipstone N.A., and Crabtree G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357 (1992) 695-697
11. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids. New mechanisms for old drugs. N. Engl. J. Med. 353 (2005) 1711-1723
12. Larsen C.P., Pearson T.C., Adams A.B., Tso P., Shirasugi N., Strobertm E., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5 (2005) 443-453
13. Haanstra K.G., Ringers J., Sick E.A., Ramdien-Murli S., Kuhn E.M., Boon L., et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 75 (2003) 637-643
14. Allison A.C., Hovi T., Watts R.W., and Webster A.D. Immunological observations on patients with the Lesch-Nyhan syndrome and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 2 (1975) 1179-1183
15. Koch M.J., and Brennan D.C. Leflunomide: is there a place for its use in transplantation?. Curr Opin Transplant 8 (2003) 317-322
16. Vanrenterghem Y., van Hooff J.P., Klinger M., Wlodarczyk Z., Squifflet J.P., Mourad G., et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patient. Transplantation 78 (2004) 9-14
17. Coulthard S., and Hogarth L. The thiopurines: an update. Invest. New Drugs 23 (2005) 523-532
18. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N. Engl. J. Med. 313 (1985) 337-342
19. Morris P.J., and Russell N.K. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 81 (2006) 1361-1367
20. Vieira C.A., Agarwal A., Book B.K., Sidner R.A., Bearden C.M., Gebel H.M., et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. safety, pharmacodynamics, and pharmacokinetics. Transplantation 77 (2004) 542-548
21. Veenstra D.L., Best J.H., Hornberger J., Sullivan S.D., and Hricik D.E. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am. J. Kidney Dis. 33 (1999) 829-839
22. Szczech L.A., Berlin J.A., Aradhye S., Grossman R.A., and Feldman H.I. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J. Am. Soc. Nephrol. 8 (1997) 1771-1777
23. Webster A., Pankhurst T., Rinaldi F., Chapman J.R., and Craig J.C. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database Syst. Rev. 2 (2006) (CD0004756)
24. Calne R.Y., White D.J., Thiru S., Evans D.B., McMaster P., Dunn D.C., et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2 (1978) 1323-1327
25. European multicenter trial. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicenter trial. Lancet 2 (1983) 986-989
26. Kahan B.D. Cyclosporine. N. Engl. J. Med. 321 (1989) 1725-1738
27. Calne R.Y., Rolles K., White D.J., Thiru S., Evans D.B., McMaster P., et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet 2 (1979) 1033-1036
28. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., and Chapman J.R. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349 (2003) 2326-2333
29. Halloran P., Mathew T., Tomlanovich S., Groth C., Hooftman L., and Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of 3 randomized, double blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63 (1997) 39-47
30. Ciancio G., Miller J., and Gonwa T.A. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 80 suppl2 (2005) S191-S200
31. Jordan M.L., Shapiro R., Jensen C.W., Scantlebury V., Fung J., Tzakis A., et al. FK506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant. Proc. 23 (1991) 3078-3082
32. Webster A.C., Woodroffe R.C., Taylor R.S., Chapman J.R., and Craig J.C. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data. BMJ 331 (2005) 810
33. Chapman T.M., and Keating G.M. Basiliximab: a review of its use as induction in renal transplantation. Drugs 63 (2003) 2803-2835
34. Trofe J., Hirsch H.H., and Ramos E. Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl. Infect. Dis. 8 (2006) 86-94
35. Ponticelli C. Steroid-sparing strategies. Transplant. Proc. 37 (2005) 3597-3599
36. Land W., and Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 80 suppl2 (2005) S221-S234
37. Webster A.C., Lee V.W., Chapman J.R., and Craig J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81 (2006) 1234-1248
38. Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. J. Am. Soc. Nephrol. 14 (2003) 1940-1948
39. Diekmann F., and Campistol J.M. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol. Dial. Transplant. 21 (2006) 562-568
40. Swanson S.J., Hale D.A., Mannon R.B., Kleiner D.E., Cendales L.C., Chamberlain C.E., et al. Kidney transplantation with rabbit antithymocyte globunin induction and sirolimus therapy. Lancet 360 (2002) 1662-1664
41. Knechtle S.J., Pirsch J.D., H Fechner Jr. J., Becker B.N., Friedl A., Colvin R.B., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 3 (2003) 722-730
42. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353 (2005) 770-781
43. Jordan S. IVIg vs plasmapheresis for desensitization: which is better?. Am. J. Transplant. 6 (2006) 1510-1511
44. Muthukumar T., Dadhania D., Ding R., Snopkowski C., Naqvi R., Lee J.B., et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N. Engl. J. Med. 353 (2006) 2342-2351
45. Anglicheau D., Thervet E., and Legendre C. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 78 (2004) 311-315
46. Zand M.S. Immunosuppression and immune monitoring after renal transplantation. Semin. Dial. 18 (2005) 511-519
47. Bohmig G.A., Regele H., and Horl W.H. Protocol biopsies after kidney transplantation. Transpl. Int. 18 (2005) 131-139